08.13.15
Marathon Pharmaceuticals LLC, a biopharmaceutical company focused on developing treatments for rare diseases and neurological disorders, named Babar Ghias its chief financial officer.
In his new role, Ghias will have primary day-to-day responsibility for planning, implementing, managing and controlling all financial-related activities of the company. Ghias will also oversee corporate development activities for Marathon including transactions, financing, investor relations and the development of beneficial relationships with financial investors, pharmaceutical companies and investment bankers.
Ghias, 36, most recently served as Marathon’s vice president of strategy and corporate development. Previously, Ghias worked for Credit Suisse in the mergers and acquisitions group in New York and London, where he led the execution of more than $80 billion in transactions for global health care clients.
In his new role, Ghias will have primary day-to-day responsibility for planning, implementing, managing and controlling all financial-related activities of the company. Ghias will also oversee corporate development activities for Marathon including transactions, financing, investor relations and the development of beneficial relationships with financial investors, pharmaceutical companies and investment bankers.
Ghias, 36, most recently served as Marathon’s vice president of strategy and corporate development. Previously, Ghias worked for Credit Suisse in the mergers and acquisitions group in New York and London, where he led the execution of more than $80 billion in transactions for global health care clients.